Outset Medical
111 hedge funds and large institutions have $2.09B invested in Outset Medical in 2020 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 43 increasing their positions, 13 reducing their positions, and 16 closing their positions.
231% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 13
169% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 16
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
31% more funds holding
Funds holding: 85 → 111 (+26)
19% more capital invested
Capital invested by funds: $1.76B → $2.09B (+$327M)
0.04% less ownership
Funds ownership: 5.88% → 5.84% (-0.04%)
Top Buyers
| 1 |
BlackRock
New York
|
+$37.3M |
| 2 |
TCM
TimesSquare Capital Management
New York
|
+$33.2M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$30.3M |
| 4 |
JP Morgan Chase
New York
|
+$26M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$24.3M |
Top Sellers
OM Hedge Fund Activity: Q4 2020 in Review
111 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Outset Medical (OM) for Q4 2020, worth a combined $2.09B — up 19% from $1.76B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new OM positions and 16 closed out — a net gain of 27 holders — while 43 added to existing stakes and 13 trimmed.
The largest buyer was BlackRock, adding an estimated $37.3M. The largest seller was Warburg Pincus, cutting an estimated $218M.
- 111 institutional investors held Outset Medical (OM) as of Q4 2020, up from 85 in Q3 2020.
- Funds reported $2.09B of Outset Medical stock for Q4 2020, up 19% quarter-over-quarter.
- 43 funds opened new Outset Medical positions in Q4 2020 and 16 closed out, a net change of +27 holders.
- The largest Outset Medical buyer in Q4 2020 was BlackRock, an estimated $37.3M added.
- The largest Outset Medical seller in Q4 2020 was Warburg Pincus, an estimated $218M sold.
Based on aggregated 13F filings for Q4 2020.